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Abstract 
The V(D)J recombination forms the immunoglobulin genes by joining the variable (V), diversity (D), and 
joining (J) germline genes. Since variations in germline genes have been linked to various diseases, personalized 
immunogenomics aims at finding alleles of germline genes across various patients. Although recent studies 
described algorithms for de novo inference of V and J genes from immunosequencing data, they stopped short 
of solving a more difficult problem of reconstructing D genes that form the highly divergent CDR3 regions and 
provide the most important contribution to the antigen binding. We present the IgScout algorithm for de novo D 
gene reconstruction and apply it to reveal new alleles of human D genes and previously unknown D genes in 
camel, an important model organism in immunology. We further analyze non-canonical V(DD)J recombination 
that results in unusually long tandem CDR3s and thus expands the diversity of the antibody repertoires. We 
demonstrate that tandem CDR3s represent a consistent and functional feature of all analyzed 
immunosequencing datasets, reveal ultra-long tandem CDR3s, and shed light on the mechanism responsible for 
their formation.  
INTRODUCTION 
Antibodies provide specific binding to an enormous range of antigens and represent a key component 
of the adaptive immune system. The antibody repertoire is generated by somatic recombination of the 
V (variable), D (diversity), and J (joining) germline gene segments. Immunosequencing has emerged 
as a method of choice for generating millions of reads that sample antibody repertoires and provide 
insights into monitoring immune response to disease and vaccination (Turchaninova et al., 2016).  
Information about all germline genes in an individual is a pre-requisite for analyzing 
immunogenomics data. However, nearly all immunogenomics studies rely on the population-level 
germline genes rather than germline genes in a specific individual that the immunosequencing data 
originated from. This approach is deficient since the set of known germline genes is incomplete 
(particularly for non-Europeans) and contains alleles that resulted from sequencing and annotation 
errors (Wang et al., 2008, Ralph and Matsen, 2017). Moreover, it is non-trivial to figure out which 
known allele(s) is present in a specific individual since the widespread practice of aligning each read 
to its closest germline gene results in high error rates (Ralph and Matsen, 2017). These errors hide the 
identity of the individual germline genes, make it difficult to analyze somatic hypermutations (SHM) 
and complicate studies of antibody evolution (Yaari et al., 2012, McCoyet al., 2015, Cui et al., 2016).  
Personalized immunogenomics (i.e., identifying individual germline genes) is important since 
variations in germline genes have been linked to various diseases (Watson and Breden, 2012), 
differential response to infection, vaccination, and drugs (Parameswaran et al., 2013, Chang et al., 
2017), aging (Boyd et al., 2013), and disease susceptibility (Kidd et al., 2012, Watson and Breden, 
2012, Avnir et al., 2016). However, since the International ImMunoGeneTics (IMGT) database is 
incomplete even in the case of well-studied human germline genes (Collins et al., 2015), there exist 
still unknown human allelic variants that are difficult to differentiate from SHMs. In the case of 
immunologically important but less studied model organisms, such as camels or sharks, the germline 
genes remain largely unknown. Unfortunately, since assembling the highly repetitive immunoglobulin 
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locus from whole genome sequencing data faces challenges (Luo et al., 2017), the efforts like the 
1000 Genomes Project have resulted only in limited progress towards inferring the population-wide 
census of germline genes (Luo et al., 2017, Yu et al., 2017, Watson et al., 2017).  
In addition to personalized immunogenomics, the incompleteness of the IMGT database 
negatively affects analysis of monoclonal antibodies. Existing tools for antibody sequencing from 
tandem mass spectra (Bandeira et al., 2008, Castellana et al., 2010) rely on a comprehensive database 
of V, D, and J genes to assemble tandem mass spectra into an intact antibody. Lack of such databases 
for many species limits applications of Valens (Digital Proteomics), SuperNova (Protein Metrics), and 
other software tools for antibody sequencing.  
Although the personalized immunogenomics approach was first proposed by Boyd et al., 
2010, the manual analysis in this study did not result in a software tool for inferring germline genes. 
Gadala-Maria et al., 2015 developed the TIgGER algorithm for inferring germline genes and used it 
to discover eleven novel allelic V segments. However, Gadala-Maria et al., 2015 stopped short of de 
novo reconstruction of the germline genes and acknowledged that it is important to develop 
algorithms for finding diverged alleles that TIgGER is not able to find. In the case of V and J genes, 
this challenge was addressed by Corcoran et al., 2016, Zhang et al., 2016, and Ralph and Matsen, 
2017. However, as Ralph and Matsen, 2017 commented, the more challenging task of de novo 
reconstruction of D genes remains elusive. This is unfortunate since D genes contribute to the 
complementarity determining region 3 (CDR3) that covers the junctions between V, D, and J genes 
and represents the highly divergent part of antibodies. We describe the IgScout algorithm for de novo 
inference of D genes and apply it to diverse immunosequencing datasets.  
Although many studies analyzed patterns of V-D-J pairing (Kidd at el., 2017; Kirik et al., 
2017), there is still a shortage of studies of unusual recombination events such as V(DD)J 
recombination incorporating two D genes into a single unusually long tandem CDR3. Meek et al., 
1989 were the first to reveal a few tandem CDR3s, thus confirming the V(DD)J recombination 
conjecture put forward by Kurosawa and Tonegawa, 1982.  However, since tandem CDR3s are rare, 
they remained elusive for the next two decades and Corbett et al., 1997 and Watson et al., 2006 even 
argued that tandem CDR3s found in Meek et al., 1989 represent artifacts. However, Briney et al., 
2012 and Larimore et al., 2012 demonstrated that tandem CDR3s do exist (at frequency 1 per 800 B-
cells) by analyzing high-throughput immunosequencing datasets.  
As emphasized in Briney et al., 2012, detecting V(DD)J recombination has to be done with 
caution since it is often confused with standard V(D)J recombination. Although they came up with a 
heuristic for detecting tandem CDR3s, there is still no software for detecting tandem CDR3s and it 
remains unclear how many tandem CDR3s found in Briney et al., 2012 represent false positives. We 
thus extended the functionality of the IgScout algorithm to finding tandem CDR3s and revealed that 
V(DD)J recombination is a functional (rather than aberrant) feature with frequency varying from 1 per 
200 to 1 per 2500 B-cells across various datasets. Finally, we revealed ultra-long tandem CDR3s and 
shed light on the mechanism responsible for their formation.  
RESULTS 
Immunosequencing datasets. We analyzed the following datasets described in the Supplemental 
Note “Immunosequencing datasets”:  
● HEALTHY: 14 datasets from 14 healthy human donors, 
● ALLERGY: 24 datasets from six allergy patients (Landais et al., 2017), 
● HIV: 13 datasets from two HIV-infected patients (Levin et al., 2017), 
● PROJECT10: 600 datasets from various humans resulting from ten NCBI projects  
● CAMEL: 6 datasets from three healthy camels (Li et al., 2016).  
 
Constructing CDR3 datasets. We illustrate the work of IgScout using one of the HEALTHY 
datasets (Set 1) containing heavy chain repertoires extracted from peripheral blood mononuclear cells 
(PBMC). The IgReC tool (Shlemov et al., 2017) extracted 228,619 distinct CDR3s from this dataset. 
To minimize impact of sequencing and amplification errors, we clustered similar CDR3s (differing by 
at most 3 mismatches) and constructed consensus for each cluster resulting in 98,576 consensus 
CDR3 of average length 46 nucleotides.  
Each CDR3s typically starts from a short suffix of a V gene and ends with a short prefix of a J 
gene. Since these suffixes and prefixes negatively affect reconstruction of D genes, IgScout trims 
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them as described in the Supplemental Note “Preprocessing CDR3 datasets.” This procedure reduces 
the average length of CDR3s from 46 to 30 nucleotides and results in the set of strings CDR3trimmed. 
We refer to the number of strings in CDR3trimmed as |CDR3trimmed|. 
 
Overview of human D genes. The human immunoglobulin (IGH) locus contains 27 D genes that 
vary in length from 11 to 37 nucleotides. Since two pairs of human D genes are identical, there exist 
only 25 distinct D genes. Since the IMGT database refers to D genes using rather long names and 
since these names do not reveal the ordering of D genes in the IGH loci (that is important for 
analyzing tandem CDR3s), it is difficult to visualize the IgScout results across all D genes and across 
multiple immunosequencing datasets. We thus renamed distinct human D genes from D1 to D25 in 
the increasing order of their positions in the IGH locus. The IMGT database also contains seven 
alleles of D genes denoted D2*, D2**, D3*, D8*, D10*, D15*, and D19*. See Table 1 and 
Supplemental Note “Information about human D genes” for details. 
 
Name IMGT name Position (bp) Length (nt) Name IMGT name Position (bp) Length (nt) 
D1 IGHD1-1 1,124,217 17 D14 IGHD2-15 1,145,762 31 
D2 IGHD2-2 1,126,893 31 D15 IGHD3-16 1,148,085 37 
D3 IGHD3-3 1,129,360 31 D16 IGHD4-17 1,149,211 16 
D4 IGHD4-4 1,130,497 16 D5 IGHD5-18 1,150,177 20 
D5 IGHD5-5 1,131,462 20 D17 IGHD6-19 1,152,020 21 
D6 IGHD6-6 1,133,309 18 D18 IGHD1-20 1,152,528 17 
D7 IGHD1-7 1,133,812 17 D19 IGHD2-21 1,155,168 28 
D8 IGHD2-8 1,136,508 31 D20 IGHD3-22 1,157,688 31 
D9 IGHD3-9 1,139,038 31 D21 IGHD4-23 1,158,849 19 
D10 IGHD3-10 1,139,222 31 D22 IGHD5-24 1,159,816 20 
D4 IGHD4-11 1,140,103 16 D23 IGHD6-25 1,162,180 18 
D11 IGHD5-12 1,141,070 23 D24 IGHD1-26 1,162,685 20 
D12 IGHD6-13 1,142,577 21 D25 IGHD7-27 1,178,168 11 
D13 IGHD1-14 1,143,081 17 
Table 1. Positions and lengths of human D genes. Since the IGH locus starts at the end of the 14th 
chromosome, positions are given with respect to its reverse complementary sequence. Green and orange cells 
correspond to two duplicated and identical D genes IGHD4-4*01 – IGHD4-11*01 (D4) and IGHD5-5*01 – 
IGHD5-18*01 (D5). 
 
Frequent k-mers in D genes. The problem of inferring germline genes can be formulated as the 
Trace Reconstruction Problem (Mitzenmacher, 2009) in information theory described in the Methods 
section. IgScout is a heuristic for solving this problem that is inspired by the RepeatScout algorithm 
for de novo repeat finding (Price et al., 2005) and that is based on analyzing frequent k-mers in 
CDR3s. We illustrate the work of IgScout using k-mers of size 15 (all human D genes are longer than 
15 nucleotides except for 11 nucleotide long gene D25).  
The human D genes contain 305 15-mers. We classify a k-mer as known if it occurs in a 
human D gene (from D1 to D25), mutated if it differs from a known k-mer by a single substitution, 
and trimmed if it contains a known (k-2)-mer. All other k-mers are called foreign. 27% of strings in 
the CDR3trimmed dataset contain a known 15-mer and 35% contain either a known, or a mutated, or a 
trimmed 15-mer.  
We classify a k-mer as common if its abundance exceeds fraction* |CDR3trimmed| (the default 
value fraction=0.001). Figure 1 and the Supplemental Note “Common k-mers” present distributions 
of frequencies of all common 15-mers in various datasets. Although the vast majority of common k-
mers are known, mutated, or trimmed, some of them are foreign. These foreign common k-mers have 
to be treated with caution since they may trigger false positive inferences of D genes.  
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Figure 1. Abundances of all 443 common 15-mers (top) and the motif logo constructed for the most 
abundant 15-mer CGATTTTTGGAGTGG in the CDR3trimmed dataset (bottom). (Top) The CDR3trimmed 
dataset contains 91% of all 15-mers appearing in human D genes (all 15-mers in human D genes are unique, i.e., 
appear in a single D gene). 443 common 15-mers in the CDR3trimmed set have abundances varying from 83 to 
3141. The y–axis represents the number of common 15-mers with given abundance (in logarithmic scale). Red, 
yellow, violet, and blue bars represent the number of common 15-mers with given abundance among known, 
mutated, trimmed, and foreign 15-mers, respectively There exist 175 known, 195 mutated, 70 trimmed, and 3 
foreign common 15-mers. The histogram represents 100 bins of width 30 each. (Bottom) The 
ATTACGATTTTTGGAGTGGTTAT is the initial 28-nucleotide long sequence formed by positions in the 
motif logo with high information content (Crooks et al., 2004). After extending this 28-mer, IgScout 
reconstructed the 30-mer GTATTACGATTTTTGGAGTGGTTATTAT that is a substring of the 33-nucleotide 
long D3 (IGHD3-3) gene GTATTACGATTTTTGGAGTGGTTATTATacc shown below the logo.   
 
From frequent k-mers to D gene reconstruction. IgScout selects a most abundant k-mer in the 
CDR3trimmed dataset, aligns all CDR3 that contain this k-mer (using this k-mer as the alignment seed), 
and constructs the motif logo of the resulting alignment (Figure 1). It further trims all positions of the 
motif logo with the information content below IC (the default value IC=0.5) and computes the 
consensus string. Afterwards, it extends the consensus strings to the right and to the left to construct a 
putative D gene as described in the Methods section. Finally, the algorithm removes the sequences 
that contain k-mers from the identified putative D gene from the set CDR3trimmed, finds a most 
abundant k-mer in the resulting dataset, and iterates. IgScout stops when a most abundant k-mer is not 
a common k-mer (see Supplemental Notes “IgScout pseudocode,” “IgScout parameters,” and 
“Benchmarking IgScout on simulated immunosequencing datasets”). Figure 2 demonstrates that 
IgScout reconstructs many known human D genes.  
Similarly to the existing tools for reconstructing V and J genes (that typically trim a few 
nucleotides in the beginning/end of the reconstructed genes), IgScout also trims a few nucleotides in 
the beginning/end of the reconstructed D genes. Although lowering the IC threshold would reduce the 
number of trimmed nucleotides, we decided not to do it since lowering this parameter may result in 
erroneous reconstructions and since the trimmed nucleotides hardly affect the downstream 
applications of IgScout. See Supplemental Note: “How trimmed (rather than complete) D genes affect 
the downstream analysis of immunosequencing datasets”. 
Indeed, the personalized immunogenomics applications (such as the discovery of “deficient” 
germline variants that lead to poor responses to vaccination (Avnir et al., 2016)) are hardly affected 
by the fact that all existing tools for inferring the V, D, and J genes trim a few nucleotides from the 
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ends. Reconstruction of monoclonal antibodies from tandem mass spectra and various 
proteogenomics applications are also hardly affected by this trimming. Moreover, in the case of 
human germline genes (and other genomes with well-characterized germline genes) the trimmed 
nucleotides can be tentatively reconstructed based on similarity with known germline genes (as has 
been done in previous studies of V and J genes). The antibody analysis and engineering in model 
organisms can also be done with partial D genes.  
 
 
Figure 2. IgScout results on the CDR3trimmed dataset. Each row shows a reconstructed string (strings are 
inferred in the order from the top to the bottom). Dark green segments correspond to reconstructed substrings of 
human D genes (flanking non-reconstructed nucleotides are shown in standard green). The most frequent 15-
mers that were used for reconstructing the corresponding D genes are shown in red (their abundances are shown 
on the left). The reconstructed substring of the D2 gene (IGHD2-2) also occurs in D2* and D2** genes. 17 
strings reconstructed by IgScout represent substrings of 17 human D genes. IgScout misses short prefixes and 
suffixes of D genes: 1.4 nucleotides on the left and 1.7 nucleotides on the right, on average for the Set 1 dataset 
(0.9 nucleotides on the left and 1.5 nucleotides on the right, on average after combining reconstructions over all 
HEALTHY datasets). IgScout did not reconstruct eight human D genes: D1 (IGHD1-1), D4 (IGHD4-4), D7 
(IGHD1-7), D13 (IGHD1-13), D18 (IGHD1-20), D21 (IGHD4-23), D23 (IGHD6-25), and D25 (IGHD7-27) 
that contributed to few CDR3 in the Set 1. These genes have the following abundances of their most frequent 
15-mers: 43 for D1, 59 for D4, 83 for D7, 0 for D13, 33 for D18, 75 for D21, 0 for D23, and 0 for D25. 
 
Reconstruction of human D genes. Figure 3 illustrates that IgScout reconstructed 18 out of 25 
human D genes across all HEALTHY datasets, Supplemental Note “Summary of IgScout results 
across diverse immunosequencing datasets” describes inference of 20 human D genes across multiple 
immunosequencing datasets. Supplemental Note “Reconstructing variants of human D genes” 
describes inference of 5 allelic variants of the D7, D10, D15, D16, and D21 genes, However, since 
variations in D7, D16, and D21 genes affect the first or last nucleotides of the corresponding D genes, 
they likely represent computational artifacts caused by abundant nucleotides at the flanking positions 
of the D genes within CDR3s. In contrast, variations of the D10 and D15 genes (referred to as D10+ 
and D15+, respectively) have mutations in the middle of D genes (Figure 3). Thus, since they were 
inferred from multiple datasets (Set 5 and Set 7 for D10+, and Set 5, Set 7, Set 9, and Set 13 for 
D15+), they likely represent previously unknown allelic variants. Supplemental Note “Reconstructing 
variants of human D genes” illustrates that 50 (46) samples among 600 samples in the PROJECTS10 
dataset support D10+ (D15+) variants and presents two more variants D10++ and D15++.  
To demonstrate that D10+ and D15+ indeed represent new variants of D10 and D15 genes, 
we analyzed 40 whole genome sequencing datasets from the population-wide study of esophageal 
cancer (PRJNA427604 project) and searched for exact occurrences of D10+ and D15+ in reads. Both 
variations were detected in 5 out of 40 datasets (SRR6435661, SRR6435676, SRR6435686, 
SRR6435691, and SRR6435692) with the number of reads supporting D10+ (D15+) varying from 8 
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to 14 (30 to 58) across these five datasets.  See Supplemental Note “How IgScout results are affected 
by the number of consensus CDR3s and cell types”. 
 
 
Figure 3. De novo reconstructions of D genes across all HEALTHY datasets (top) and allelic variants 
D10+ and D15+ inferred by IgScout (bottom). (Top) Genes reconstructed at consecutive steps of IgScout for 
all HEALTHY datasets. Rows correspond to the datasets and columns correspond to the IgScout steps. Each 
cell is marked by a reconstructed D gene (each D gene is assigned a unique color). Cells marked with the “+” 
sign refer to strings that differ from known D genes by and correspond to putative novel variants (shown within 
a circle). (Bottom) Allelic variants D10+ and D15+ inferred by IgScout. Differences from human D genes and 
their allelic variants listed in the IMGT database are shown in red. 
 
Reconstruction of camel D genes. Although camel V genes were inferred in Conrath et al., 2003, 
camel D genes remain unknown. We analyzed six CAMEL datasets from three camels (VH and VHH 
libraries for each camel) labeled as Camel 1VH, 1VHH, 2VH, 2VHH, 3VH, and 3VHH (Li et al., 
2016). While the VH libraries contain the heavy chain of the conventional (both heavy and light 
chain) camel antibodies, the VHH libraries contain the heavy chains of the single-chain nano 
antibodies (Leslie, 2018).  
We extracted camel CDR3s by aligning camel antibody repertoires against the known camel 
V and J genes using the IgReC tool (Shlemov et al., 2017). For the Camel 1VH dataset, IgScout 
constructed 60,066 consensus CDR3 sequences of average length 48 nucleotides. The CDR3trimmed 
dataset for Camel 1VH has total length 1,400,360 nucleotides (the average length 23 nt).  
IgScout reconstructed four D genes in the case of the Camel 1VH dataset that we refer to as 
D1, D2, D3, and D4 (see Supplemental Note “Reconstructing camel D genes”). It reconstructed four 
putative D genes in datasets Camel 1VHH, and Camel 2VH, and three putative D genes in the 
remaining three camel datasets (17 strings in total) that are largely consistent with genes D1, D2, D3, 
and D4 derived from the Camel 1VH dataset (previous studies assumed that the camel genome has a 
single germline D gene (Conrath et al., 2003). Supplemental Note “Reconstructing camel D genes” 
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illustrates that all camel D genes are shared between the VH and VHH datasets. Supplemental Note 
“Usage of camel D genes” demonstrates that the camel D genes have strikingly different usage in the 
VH and VHH antibodies.  
 
D gene usage. 25 human D genes form a set of strings that we refer to as D-Genes. Given an arbitrary 
string Target, a string D from D-Genes, and a parameter k, we say that a string Target is formed by D 
if it contains a k-mer from D but does not contain k-mers from other strings in D-Genes (the default 
value k=11). We classify a CDR3 as traceable if it is formed by a D gene and non-traceable, 
otherwise. The percentage of traceable CDR3s is rather conservative across all HEALTHY datasets: 
≈60% of CDR3s in the HEALTHY datasets are traceable (Supplemental Note “Traceable CDR3s”).  
Given a set of strings Strings and a string D from D-Genes, we define usage(Strings, D-
Genes, D) as the fraction of traceable strings in Strings formed by the string D. We are interested in 
usage(CDR3trimmed, D – Genes, D) for each human D gene.  Supplemental Note “Traceable CDR3s” 
analyzes the usage of all human D genes across all HEALTHY datasets. Supplemental Note “D gene 
classification by IgScout and IgBlast” compares IgScout and IgBlast classification of D genes 
forming CDR3s.   
We analyzed the usage of known and novel allelic variants (D10+ and D15+) across all 
HEALTHY datasets. Figure 4 reveals that usage of allelic variants of D2 and D3 is consistent across 
all datasets with D2* and D3 as dominant variants. However, the Set 5 has different dominant variants 
as compared to other datasets: D8* (compared to D8 in all other datasets); D10+ (compared to D10 in 
all other datasets); and D19 (compared to D19* in all other datasets). The variant D15+ is dominant in 
Sets 5, 7, 9, and 13, while the D15 gene is dominant in the remaining eight datasets.  
 
 
Figure 4. Usage of D genes with known and novel allelic variants across all HEALTHY datasets. 
Horizontal black lines sub-partition the matrix into six sub-matrices corresponding to allelic variants of D2 
(IGHD2-2), D3 (IGHD3-3), D8 (IGHD2-8), D10 (IGHD3-10), D15 (IGHD3-16), and D18 (IGHD1-20). For 
each D gene and each dataset, we computed the percentage of usage of each variant. Values in cells vary from 0 
(blue) to 100 (red). White cells correspond to values ≈50% and likely represent cases when a single individual 
carries different variants of a given D genes on two different chromosomes. 
 
Tandem CDR3s. Given strings D and D’, and a parameter k, we say that a string Target is formed by 
D and D’ if it contains k-mers from both D and D’ and a k-mers from D’ starts after a k-mer from D 
ends. Since tandem CDR3s represent a small fraction of all CDR3s, we set the default value k=11 
(rather than k=15 for all CDR3s) to increase the number of identified tandem CDR3s. Although a 
smaller value of k may lead to identification of pseudo-tandem CDR3s, the Methods section describes 
how to filter out such pseudo-random CDR3s.  
There exists 187 tandem CDR3s formed by two D genes in the CDR3trimmed dataset (Figure 5). 
We denote the longest substring between a tandem CDR3 Target and D (Target and D') as Dmatch 
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(D'match) and represent a tandem CDR3 Target as a concatenate of five strings prefix * Dmatch * middle * 
D'match * suffix. We define the span of a tandem CDR3 formed by D and D' as the substring Dmatch * 
middle * D'match and inter-D insertion as the substring middle (Figure 5).   
Briney et al., 2012 emphasized that detecting tandem CDR3s has to be done with caution 
since they are often confused with pseudo-tandem CDR3s formed by the standard V(D)J 
recombination (Figure 5). The Methods section describes how IgScout detects pseudo-tandem 
CDR3s. 
 
 
Figure 5. A tandem CDR3 formed by genes D3 (IGHD3-3) and D5 (IGHD5-5) (top), a pseudo-tandem 
CDR3 formed by genes D10 and D15 (middle), and the tandem matrix for all tandem CDR3s across all 
HEALTHY datasets (bottom). (Top) A tandem CDR3 with Dmatch=GTATTAGGATTTTTGGAGTGGTTAT, 
middle=CAGCCA, and D'match=GTGGATACAGCTATGG. (Middle) The pseudo-tandem CDR3, formed by 
genes D10 (IGHD3-10) and D15 (IGHD3-16). This CDR3 was formed by a single gene D10 (IGHD3-10) with 
three mutations (shown in red). IgScout filters out most pseudo-tandem CDR3s. (Bottom) The number in a cell 
(i,j) shows the total number of tandem CDR3s formed by genes Di and Dj across all HEALTHY datasets. Empty 
cells correspond to pairs of D genes that do not form tandem CDR3s. Genes D4 and D5 appear in two copies in 
the IGH loci. The second copy of D4 (IGHD4-11) appears between D10 (IGHD3-10) and D11 (IGHD5-12). 
The second copy of D5 (IGHD5-18) appears between D16 (IGHD4-17) and D17 (IGHD6-19). The vast 
majority of tandem CDR3 correspond to cells in the upper half of the matrix. The only populated column in the 
lower part of the tandem matrix corresponds to the D5 gene and likely results from tandem CDR3s formed by 
the second copy of D5 in the IGH locus. 
 
Tandem bias. There exists 114 tandem CDR3s in the Set 1 dataset and 1900 tandem CDR3s across 
all HEALTHY datasets. Figure 5 represents all tandem CDR3s as a tandem matrix and reveals that 
the vast majority of them correspond to cells in the upper half of this matrix. If tandem CDR3s were 
computational artifacts, we would expect similar numbers of CDR3s in the upper and lower parts of 
the tandem matrix. We define the tandem bias as Nupper / (Nupper + Nlower), where Nupper and Nlower is the 
sum of entries in the upper and lower parts of the tandem matrix, respectively (we assume that the 
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main diagonal belongs to the lower part of the matrix). The tandem bias varies from 0.03 % to 0.21% 
across various datasets (see Supplemental Note: “Analysis of tandem CDR3s).  
Since most pairs of D genes in tandem CDR3s contribute to the upper part of the tandem 
matrix (and thus follow the order of D genes in the IGH locus), some entries in the lower part of the 
tandem matrix may reveal possible duplications of D genes, e.g., the D20 row in the lower part of the 
tandem matrix in Figure 5 reveals many tandem CDR3s. Analysis of the hepatitis patient 1776 in the 
PROJECTS10 dataset (Galson et al., 2016) revealed particularly many entries in the D20 column in 
the lower part of the tandem matrix, suggesting a duplication of the D20 gene in this patient (see 
Supplemental Note “Analysis of tandem CDR3s”). Kidd et al., 2016 analyzed biases in the D-J 
pairing and also suggested that D20 may be duplicated in some individuals. 
 
Ultra-long tandem CDR3s reveal unusual recombination events. 1900 tandem CDR3s across all 
HEALTHY datasets contain 1081 distinct inter-D insertions, varying in length from 0 to 153 
nucleotides. The two longest inter-D insertions (denoted I1 and I2) appear in the Set 1 and have length 
153 nucleotides. They are formed by genes D9 and D10, differ by a single nucleotide, and appear in 
CDR3s differing by 6 nucleotides. Surprisingly, the inter-D insertion I2 coincides with the sequence of 
the IGH locus between the D9 and D10 genes. Germline D genes are flanked by 12-nucleotide long 
recombination signal sequences (RSSs) and the inter-D insertion I2 starts with the right RSS of D9 and 
ends with the left RSS of D10 (Supplemental Note “Ultra-long tandem CDR3s”).  
Thus, ultra-long tandem CDR3s reveal unusual RSS skipping events during somatic 
recombination: skipping the right RSS of D9 and left RSS of D10 led to a tandem CDR3 representing 
a concatenate D9 + I2 + D10. The existing immunosequencing protocols are likely to miss ultra-long 
immunoglobulins since they are not designed to capture the abnormally long variable regions 
(exceeding ~400 nt). We captured reads containing ultra-long tandem CDR3s because the 300-
nucleotide long paired reads (overlapping by only 50 nucleotides) in the Set 1 are longer than reads 
used in most other immunosequencing datasets. Thus, even if ultra-long tandem CDR3s were 
common, they would likely remain below the radar of most immunosequencing studies.   
 
Tandem CDR3s contribute to adaptive immune response. We investigated whether tandem 
CDR3s contribute to the adaptive immune response by analyzing their isotypes. Since IgG, IgA, and 
IgE isotypes occur in plasma and memory B cells subjected to the antibody-antigen interactions, these 
isotypes they indicate (in difference from IgM isotypes common in memory and naïve B cells) that 
the corresponding antibodies participate in the adaptive immune response.  
We inferred isotypes in the ALLERGY and HIV datasets using markers described in Levin et 
al., 2017 (Figure 6), the vast majority of tandem CDR3s from the ALLERGY dataset correspond to 
the IgM isotype and thus are produced by memory and naïve B cells. In contrast, ~60% of tandem 
CDR3s in the HIV dataset correspond to the IgG type. This observation suggests that tandem CDR3s 
in the HIV-infected patients arise from immunoglobulins that are produced by plasma cells and thus 
might contribute to the immune response against HIV antigens. 
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Figure 6. Fractions of IgM, IgG, IgE, and IgA isotypes representing tandem CDR3s in the repertoires 
from the ALLERGY and HIV datasets. 
DISCUSSION  
Since many human germline alleles remain unknown (particularly for non-European subjects), 
missing alleles may mislead clinical decisions (Xochelli et al., 2015) and lead to erroneous derivation 
of clonal lineages due to misinterpretations of SHMs. Thus, finding new germline alleles and building 
personalized sets of germline genes for each individual is important for downstream analysis of 
immunosequencing datasets. 
Although there exists a number of tools for inferring V and J genes (Corcoran et al., 2016, 
Zhang et al., 2016, Ralph and Matsen, 2017), a more difficult problem of reconstructing D genes 
remains open. IgScout aims to reconstruct all D genes explaining a large percentage of the VDJ 
recombination in an antibody repertoire rather than to reconstruct all D genes. The IMGT database 
reflects the genomic diversity of D genes but not their recombinant diversity (information about 
rearrangements, transcription, and translation of D genes). Since assemblies of the highly repetitive 
IGH loci are fragmented and error-prone (Matsuda et al., 1998; Watson et al., 2012; Watson et al., 
2013. Luo et al., 2017), reconstruction of all germline genes from the whole-genome sequencing data 
is a difficult problem. Although the IGH locus is extremely diverse (Watson et al., 2017), it remains 
largely unknown how it varies across the human population Moreover, even in the case when the IGH 
locus is correctly assembled, prediction of the functional germline genes is a non-trivial problem 
(Wang et al., 2008; Collins et al., 2015).  
Immunosequencing datasets reflect the recombinant diversity of antibody repertoires and thus 
complement the genomic datasets. If some D genes do not contribute to the VDJ recombination (e.g., 
our analysis suggests that genes D1, D13, D18, D23, and D25 do no significantly contribute to VDJ 
recombination in any of the analyzed datasets), they have limited contribution to immune response. In 
this paper, we focused on reconstructing D genes shaping the recombinant diversity rather than all D 
genes. 
IgScout reconstructed 20 out of 25 human D genes across multiple datasets and missed genes 
D1, D13, D18, D23, D25 that form a small number of CDR3s (less than 0.1% each) across all 
analyzed datasets. It remains unclear whether some of these genes ever contribute to any CDR3s, for 
example genes D13 and D23 do not form any CDR3s in most datasets (few CDR3s formed by these D 
genes in some datasets may represent computational artifacts).  
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IgScout revealed four new allelic variants (D10+, D10++, D15+, and D15++), thus increasing 
the number of known variants of human D genes from seven to eleven. These new variants are 
unlikely to be computational artifacts since they were found in dozens immunosequencing datasets 
from distinct individuals and many whole genome sequencing datasets. The frequency of the already 
known Single Nucleotide Polymorphisms (SNPs) in D genes exceeds the frequency of SNPs in the 
entire human genome by two orders of magnitude (12 SNPs for all D genes of total length only 288 
nucleotides). One possible explanation is the selection pressure for variants of D genes forming 
CDR3s that are particularly effective against emerging pathogens.   
Although IgScout revealed four novel variants of human D genes and inferred camel D genes, 
these genes will not be included in the IMGT database since they haven’t been experimentally 
confirmed yet. Similarly to Gadala-Maria et al., 2015, we argue that, like in other areas of genomics, 
the time has come to add such prediction to the IMGT database. For example, the lion’s share of 
genes in genomic databases represent computational predictions that haven never been experimentally 
confirmed. We argue that IMGT should classify alleles with varying levels of supporting evidence, 
not unlike classification systems used in other biological databases. Since the number of 
computationally predicted but not yet experimental confirmed germline genes has been steadily 
increasing, lack of depository for such predictions makes it difficult to analyze diverse 
immunosequencing datasets.   
Although IgScout is not specifically designed for reconstructing V and J genes, it turned out 
that its applications are not limited to reconstructing D genes (see Supplemental Note “De novo 
reconstruction of human J genes”). In addition to de novo reconstruction of D genes, it also detects 
tandem CDR3s. Briney et al., 2012 postulated that tandem CDR3s mostly appear in naïve B cells and 
thus do not contribute to adaptive immune response. In contrast, our analysis revealed that tandem 
CDR3s contribute to adaptive immune response since ~80% of them in the HIV dataset have been 
contributing to antigen binding.  
METHODS 
Inferring germline genes as the Trace Reconstruction Problem. In information theory, a string S 
yields a collection of traces, where each trace is independently obtained from S by substituting each 
symbol in S by another symbol from a fixed alphabet with a given probability δ. Given the traces and 
the value δ, the Trace Reconstruction Problem (Mitzenmacher, 2009) is to reconstruct the original 
string S. De novo reconstruction of D genes results in a more complex version of the Trace 
Reconstruction Problem where traces are generated by multiple strings and each trace is obtained 
from one of these strings by (i) randomly trimming it from both sides, (ii) adding a randomly 
generated prefix in the front of the string, and (iii) adding a randomly generated suffix in the end of 
the string. Given a set of such traces (modeled by a set of trimmed CDR3s extracted from an 
immunosequencing dataset), the goal is to reconstruct the original set of strings.  
 
Extending the consensus string. IgScout trims all positions of the motif logo with the information 
content below IC and computes the consensus string. Afterwards, it extracts the first k-mer of the 
consensus string and finds all CDR3s that contain this k-mer. If the position preceding the first k-mer 
in these reads has information content exceeding a threshold, IgScout adds the most frequent 
nucleotide at this position to the consensus and iterates. Afterwards, it applies a similar procedure to 
the last k-mer of the consensus string. The resulting extended consensus is reported as a putative D 
gene (Figure 1). 
 
Detecting pseudo-tandem CDR3s. Given strings Span and S, we define distancet(Span,Target) as 
the minimum Hamming distance between t-mers in Span and S. Given a parameter Δ (the default 
value Δ=5) we define the Δ-distance between strings Span and Target as distancet(S,Target) for 
t=|Span|-Δ, where |Span| stands for the length of the string Span. Finally, we define the Δ-distance 
between a string Span and a set of strings Strings as the minimum Δ-distance between Span and all 
strings in Strings.  
We computed the Δ-distance between the spans of all 187 identified tandem CDR3s in 
CDR3trimmed and all string in D-Genes. 73 out of these 187 CDR3s can be explained as CDR3s 
originating from a single D gene (for the Δ-distance threshold 3). However, the remaining 114 CDR3s 
have Δ-distance at least 9. We thus classify a CDR3 sequence Target formed by genes D and D’ as 
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pseudo-tandem if the Δ-distance between the span of this pseudo-tandem CDR3 and D-Genes does 
not exceed a predefined threshold (the default value is 3), and (truly) tandem, otherwise. See 
Supplementary Note “List of tandem CDR3s.”  
 
Availability of data and materials. IgScout is available at https://github.com/Immunotools.  
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Supplemental Note: Immunosequencing datasets 
We analyzed the following immunosequencing datasets:  
● HEALTHY: 14 datasets from healthy individuals labeled as Set 1 – Set 14 (Table A1).  
● ALLERGY: 24 datasets from allergy patients available from the NCBI project PRJEB18926 
and labeled as ALLERGY 1 – ALLERGY 24 (Table A2). 
● HIV: 13 datasets from HIV-infected patients available from the NCBI project PRJNA396773 
and labeled as HIV 1 – HIV 13 (Table A3).  
● PROJECTS10: 600 datasets from various human subjects corresponding to ten NCBI projects 
(Table A4). 
● CAMEL: 6 camel datasets labeled as Camel 1VH, Camel 1VHH, Camel 2VH, Camel 2VHH, 
Camel 3VH, and Camel 3VHH (Table A5).  
 
Datasets Set 1 – Set 9 were generated in Dr. Chudakov’s lab at Moscow Institute for Bioorganic 
Chemistry to study aging of the adaptive immune system. Datasets Set 10 – Set 14 were generated to 
study immunological response to vaccines (39). These datasets contain heavy chain repertoires 
extracted from peripheral blood mononuclear cells (PBMC) of fourteen healthy individuals. Although 
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B cells from peripheral blood contain SHMs, we do not expect to see large clonal lineages in healthy 
donors.  
 
dataset accession number # reads 
# distinct 
CDR3s 
# consensus 
CDR3s # trimmed CDR3s 
Set 1 TBA 1,611,497 228,619 98,576 82,653 
Set 2 TBA  1,497,830 226,206 93,561 75,472 
Set 3 SRR5851422 783,971 80,741 39,930 33,123 
Set 4 TBA  1,231,238 176,250 111,752 95,278 
Set 5 TBA  1,213,516 218,157 141,518 118,862 
Set 6 TBA  2,062,940 209,257 90,465 75,978 
Set 7 TBA  2,263,605 277,715 152,999 124,837 
Set 8 TBA  1,748,496 163,215 80,212 67,382 
Set 9 TBA  1,392,370 256,232 153,251 132,595 
Set 10 SRR3620050 1,309,906 379,695 129,162 102,768 
Set 11 SRR3620092 613,907 181,511 102,186 84,430 
Set 12 SRR3620100 599,674 184,143 112,820 115,005 
Set 13 SRR3620109 602,833 213,507 158,332 130,560 
Set 14 SRR3620118 497,441 212,070 144,299 119,731 
Table A1. Information about the HEALTHY immunosequencing datasets. The “# distinct CDR3s” column 
refers to the number of distinct CDR3s extracted from reads. The “# consensus CDR3s” column refers to the 
number of distinct consensus CDR3s. The “# trimmed CDR3s” column shows the number of trimmed CDR3s 
that are longer than k (the default value k = 15). Some of the listed datasets are in the process of uploading to 
SRA.  
dataset accession number # reads 
# distinct 
CDR3s 
# consensus 
CDR3s 
# trimmed 
CDR3s 
Donor 1 
ALLERGY1 ERR1812282 1,249,203 213,573 104,981 89,215 
ALLERGY2 ERR1812283 1,566,025 292,102 160,637 137,836 
ALLERGY3 ERR1812288 1,782,715 291,796 173,419 150,577 
ALLERGY4 ERR1812289 1,372,999 263145 172,202 149,626 
Donor 2 
ALLERGY5 ERR1812284 1,313,874 353,957 189,172 163,373 
ALLERGY6 ERR1812285 1,578,854 411,139 227,437 196,932 
ALLERGY7 ERR1812290 644,711 185,269 133,524 113,985 
ALLERGY8 ERR1812291 1,208,581 259,113 173,590 148,412 
Donor 3 
ALLERGY9 ERR1812286 1,260,585 174,620 72,466 62,208 
ALLERGY10 ERR1812287 2,366,528 270,805 95,473 81,552 
ALLERGY11 ERR1812292 2,116,149 350,726 184,033 157,660 
ALLERGY12 ERR1812293 1,842,407 308,770 167,897 143,617 
Donor 4 
ALLERGY13 ERR1812294 1,935,709 225,119 98,917 83,730 
ALLERGY14 ERR1812295 1,526,356 207,544 101,642 85,928 
ALLERGY15 ERR1812300 783,249 174,985 129,828 108,518 
ALLERGY16 ERR1812301 1,107,910 228,960 169,861 142,102 
Donor 5 
ALLERGY17 ERR1812296 1426885 269077 125,283 108,452 
ALLERGY18 ERR1812297 2140711 390376 190,216 166,223 
ALLERGY19 ERR1812302 942524 110675 57,414 47,864 
ALLERGY20 ERR1812303 1383359 118322 52,666 42,870 
Donor 6 
ALLERGY21 ERR1812298 2,349,277 391,293 203,739 175,067 
ALLERGY22 ERR1812299 2,137,156 357,480 187,634 160,635 
ALLERGY23 ERR1812304 1,018,489 183,855 114,532 97,957 
ALLERGY24 ERR1812305 818,062 136,659 81,853 69,686 
Table A2. Information about the ALLERGY immunosequencing datasets. The first two datasets within each 
group represent the bone marrow samples (BM) and the second two datasets represent the peripheral blood 
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samples (PBMC). For example, for the datasets ALLERGY 1 and ALLERGY 2 represent BM samples and the 
datasets ALLERGY 3 and ALLERGY 4 represent PBMC samples. 
dataset accession number # reads 
# distinct 
CDR3s 
# consensus 
CDR3s 
# trimmed 
CDR3s 
HIV1 SRR5888724 775,005 128,433 26,887 21,696 
HIV2 SRR5888725 1,961,141 246,330 55,271 42,302 
HIV3 SRR5888726 893,865 115,323 25,235 19,981 
HIV4 SRR5888727 1,914,113 241,801 54,492 41,689 
HIV5 SRR5888728 1,666,263 200,016 45,763 35,284 
HIV6 SRR5888729 1,896,887 215,481 47,593 36,450 
HIV7 SRR5888730 812,033 124,228 24,200 18,677 
HIV8 SRR5888731 1,446,869 155,623 30,938 25,815 
HIV9 SRR5888732 1,856,458 198,851 39,164 32,349 
HIV10 SRR5888733 1,138,382 115,075 28,911 24,168 
HIV 11 SRR5888734 1,371,172 145,683 32,407 26,809 
HIV 12 SRR5888735 1,460,715 128,252 19,334 16,503 
HIV 13 SRR5888736 1,485,469 108,508 25,021 20,506 
Table A3. Information about the HIV immunosequencing datasets. 
NCBI project Reference # datasets 
   PRJEB18926 (21) 24 
PRJNA396773 (28) 13 
PRJNA308641 (37) 107 
PRJNA324093 (39) 95 
PRJNA248475 (40) 32 
PRJNA308566 (41) 142 
PRJNA355402 (42) 93 
PRJNA393446 (43) 42 
PRJNA349143 (45) 24 
PRJNA430091 (46) 28 
Table A4. Information about the PROJECTS10 immunosequencing datasets. The “# datasets” column shows 
the number of datasets in each project.  
dataset accession number # reads 
# distinct 
CDR3s 
# consensus 
CDR3s 
# trimmed 
CDR3s 
Camel 1VH SRR3544217 369,502 183,973 60,006 46,326 
Camel 1VHH SRR3544218 339,758 157,938 43,880 39,701 
Camel 2VH SRR3544219 288,099 170,899 74,368 58,118 
Camel 2VHH SRR3544220 281,403 164,087 74,846 68,808 
Camel 3VH SRR3544221 347,291 176,854 79,382 61,918 
Camel 4VHH SRR3544222 343,485 150,724 59,322 53,799 
Table A5. Information about the CAMEL immunosequencing datasets. 
Supplemental Note: Preprocessing CDR3 datasets 
Although IgScout performs a more aggressive error correction (clustering CDR3s that differ by at most 
3 mismatches) than the error correction implemented in IgReC (31) repertoire construction tool, the 
resulting consensus CDR3s may still contain amplification errors. However, these errors do not corrupt 
our analysis since they typically result in the low abundance k-mers that are not considered by IgScout.  
 
To exclude suffixes (prefixes) of V (J) genes from the constructed set of CDR3s, we trimmed prefixes 
(suffixes) of CDR3s if they represent suffixes of V genes (prefixes of J genes). If fragments of known 
V and J genes were not found in a CDR3, we nevertheless cropped it by 10 nucleotides from the start 
(the end) to remove suffixes (prefixes) of mutated or still unknown V and J genes. 
Supplemental Note: Information about human D genes  
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All human D genes are located in a 30 kp long region in the human IGH locus. Figure A1 shows allelic 
variants of human D genes listed in the IMGT database.  
 
Figure A1. Allelic variants of human D genes listed in the IMGT database. Differences between various 
variants are highlighted in red. Alleles of human D genes differ from the main variants in a single mutation (D2*, 
D2**, D10*, D15*, and D19*) or two mutations at adjacent positions (D3* and D8*).  
We say that two k-mers are δ-similar if the Hamming distance between them does not exceed the 
parameter δ. To evaluate similarities between D genes, we constructed their similarity graph 
SimGraphk,δ in which each D gene corresponds to a vertex and two vertices are connected by an edge 
if the corresponding D genes contains δ-similar k-mers. The weight of the edge connecting two D genes 
in the similarity graph is defined as the number of δ-similar k-mers between these genes.  
 
Figure A2 shows non-trivial connected components of the similarity graphs SimGraph15,1 and 
SimGraph15,2 for human D genes and illustrates that connected components contain D genes from the 
same family of D genes. 
 
Since the similarity graphs SimGraph15,1 and SimGraph15,2 for camel D genes are empty, we reduced 
the parameter k from 15 to 8 and constructed the graph SimGraph8,2 for camel D genes. As Figure A 
(left) illustrates, all four camel D genes are similar to each other with respect to shared 8-mers. 
 
SimGraph15,1  
(human) 
SimGraph15,2  
(human) 
SimGraph8,2 
(camel) 
   
  
 
Figure A2. Non-trivial connected components in the similarity graphs SimGraph15,1 for human (left), 
SimGraph15,2 for human (middle), and SimGraph8,2 for camel (right) D genes. We assigned an individual color 
to each family of human D genes and to each camel D gene. The graph SimGraph15,4 consists of a single 
connected component containing all human D genes. Human D genes form seven gene families: F1 shown in red: 
D1 (D1-1), D7 (D1-7), D13 (D1-14), D18 (D1-20), D24 (D1-26); F2 shown in orange: D2 (D2-2), D8 (D2-8), 
D14 (D2-15), D19 (D2-21); F3 shown in green: D3 (D3-3), D9 (D3-9), D10 (D3-10), D15 (D3-16), D20 (D3-22); 
F4 shown in yellow: D4 (D4-4), D16 (D4-17), D21 (D4-23); F5: D5 (D5-5), D11 (D5-12), D22 (D5-24); F6 
shown in blue: D6 (D6-6), D12 (D6-13), D17 (D6-19), D23 (D6-25); F7: D25 (D7-27).  
Supplementary Note: Common k-mers  
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Table A6 provides information about common 15-mers in all HEALTHY datasets. Figure A3 illustrates 
that most 15-mers from human D genes have high abundances and low ranks.  
 
dataset 
known 
15-mers 
mutated 
15-mers 
trimmed 
15-mers 
foreign 
15-mers 
# min / max # min / max # min / max # min / max 
Set 1 175 83 / 3141 195 83 / 645 70 83 / 604 3 83 / 134 
Set 2 174 77 / 2850 185 76 / 587 68 76 / 556 3 94 / 104 
Set 3 174 34 / 1070 165 34 / 222 63 34 / 199 2 35 / 41 
Set 4 177 99 / 3921 193 96 / 739 83 96 / 728 7 96 / 131 
Set 5 169 120 / 4699 159 119 / 2252 82 119 / 1204 22 121 / 252 
Set 6 176 76 / 2483 173 76 / 547 59 77 / 520 3 91 / 114 
Set 7 174 128 / 4313 143 126 / 1001 64 126 / 877 2 129 / 130 
Set 8 168 72 / 2371 168 68 / 523 65 68 / 491 3 70 / 98 
Set 9 180 134 / 6505 234 133 / 1877 106 136 / 1728 8 135 / 278 
Set 10 180 104 / 4627 193 103 / 1319 89 103 / 763 6 112 / 185 
Set 11 176 86 / 4007 163 85 / 890 80 86 / 513 4 85 / 131 
Set 12 176 121 / 5241 162 116 / 1094 75 116 / 675 3 122 / 217 
Set 13 177 134 / 4663 176 131 / 1143 80 131 / 1066 5 135 / 175 
Set 14 175 123 / 5650 182 120 / 1309 93 120 / 1084 8 122 / 183 
Table A6. Information about known, mutated, trimmed, and foreign k-mers among common 15-mers 
across all HEALTHY datasets. The “#” columns show the number of 15-mers of each type. The “min / max” 
columns refer to the minimal / maximal abundance of 15-mers of each type.  
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Figure A3. Ranks (top) and abundances (bottom) of 15-mers from human D genes computed for the 
CDR3trimmed dataset. Each D gene of length t is shown as a sequence of t-14 cells representing its 15-mers. For 
example, the gene D1 of length 17 is shown as a sequence of 3 cells. A number within a cell represents the rank 
(top) or abundance (bottom) of the corresponding 15-mer. For example, D3 contains the most abundant 15-mer 
with rank 1 and abundance 314. Red (blue) cells correspond to low (high) values of ranks and high (low) values 
of abundances. 11-nucleotide long gene D25 is not shown. Genes D13, D23 and D25 do not contribute 15-mers 
to the CDR3trimmed dataset.  
Supplemental Note: IgScout pseudocode  
IgScout takes (i) a set Strings representing trimmed CDR3s, (ii) the k-mer size, (iii) the information 
content threshold IC, and (iv) the minimum multiplicity minMultiplicity of k-mers threshold as the input 
parameters (Figure A4). It uses the PrefixExtension and SuffixExtension subroutines for extending 
the selected k-mers to the left and to the right and generating the putative D genes. See Supplemental 
Note “IgScout parameters.”  
 
IgScout(Strings, k, IC, minMultiplicity)    
RemainingStrings ¬ Strings 
D-genes ¬ empty set 
while forever  
   D ¬ a most frequent k-mer in RemainingStrings  
   if frequency of D in Strings exceeds minMultiplicity 
      D ¬ PrefixExtension(RemainingStrings, D, k, IC)  
      D ¬ SuffixExtension(RemainingStrings, D, k, IC)  
      add string D to the set D-genes  
       Strings(D) ←all strings in RemainingStrings containing k-mers from the string D   
       remove all strings from Strings(D) from the set RemainingStrings  
   else 
      return D-genes 
 
PrefixExtension(Strings, D, k, IC)  
   prefix ¬ first k-mer in string D 
   Strings(prefix) ¬ all strings in Strings containing prefix   
   Alignment ¬ prefix-anchored alignment of all strings in Strings(prefix)  
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   previousColumn ¬ the column in Alignment preceding the first position of D    
       if information content of previousColumn exceeds IC 
          consensus ¬ a most frequent nucleotide in previousColumn  
          D ¬ the prefix-extension of the string D by the nucleotide consensus  
          PrefixExtension(Strings, D, k, IC)  
        else  
           return D 
 
SuffixExtension(Strings, D, k, IC)  
   suffix ¬ last k-mer in string D 
   Strings(suffix) ¬ all strings in Strings containing suffix   
   Alignment ¬ suffix-anchored alignment of all strings in Strings(suffix)  
   nextColumn ¬ the column in Alignment following the last position of D    
       if information content of nextColumn exceeds IC 
          consensus ¬ a most frequent nucleotide in nextColumn  
          D ¬ the suffix-extension of the string D by the nucleotide consensus  
          SuffixExtension(Strings, D, k, IC)  
       else 
          return D 
Figure A4. IgScout pseudocode. 
Supplemental Note: IgScout parameters 
IgScout stops when the most frequent k-mer in the remaining CDR3s has abundance below 
minMultiplicity=fraction*|CDR3trimmed|. We applied IgScout with various values of the parameters 
fraction = {0.0005, 0.001, 0.0015, 0.002, 0.0025, 0.003, 0.0035, 0.004} and IC = {30%, 40%, 50%, 
60%, 70%, 80%} to 14 HEALTHY immunosequencing datasets. For each launch of IgScout, we 
computed the following metrics: 
• the number of reconstructed D genes (we classify a segment as a reconstructed D gene if it is 
a substring of this D gene),  
• the average number of nucleotides missing at the start/end of the reconstructed D genes,   
• the number of novel genes (we classify a segment as novel if it does not represent a substring 
of a known D gene). Note that novel D genes may represent both allelic variants and false 
positive inferences.  
 
Figure A5 shows distributions of values of these metrics (averaged over 14 HEALTHY datasets) for 
each pair of fraction and IC values and illustrates that fraction = 0.001 and IC = 0.5 represent suitable 
parameters.  
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Figure A5. IgScout results for various values of parameters fraction and IC (the HEALTHY datasets). 
Colors correspond to various values of IC (in percentages). The distribution of the metric values for each pair 
of fraction and IC is illustrated as an error bar. The bar shows the quartiles of the distribution, the whiskers 
demonstrate the rest of the distribution, except for points that are determined as outliers. 
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Figure A6 shows multiplicities and ranks of known 15-mers after 17 iterations of IgScout (the Set 1 
dataset). IgScout stops before reconstructing the D7 gene because its most abundant 15-mer occurs in 
less than fraction=0.1% of strings in the CDR3trimmed dataset. Although decreasing the fraction threshold 
would lead to reconstructing additional D genes, it may also add false positive reconstructions. Figure 
A7 shows abundances of common 15-mers in the set of CDR3s that remain after IgScout completed its 
work.  
 
Figure A6. Ranks (top) and abundances (bottom) of 15-mers from known D genes constructed for the 
CDR3s remaining after IgScout completed its work (for the Set 1 dataset). 15-mers used for inference of D 
genes are marked with “*”.  
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Figure A7. Abundances of all 12 common 15-mers in the CDR3trimmed set after 17 iterations of IgScout. We 
removed CDR3s participating in the inference of novel D segments during the first 17 steps of the IgScout 
algorithm and analyzed all common 15-mers in the remaining 55,514 CDR3s. These 12 common 15-mers have 
abundances varying from 56 to 81. The y–axis represents the number of common 15-mers with the given 
abundance. Red, orange, and violet bars represent the number of common 15-mers with given abundance among 
common 15-mers. There exist 3 known (red bars), 8 mutated (orange bars) and 1 trimmed (violet bars) 15-mers. 
There are no foreign 15-mers among common 15-mers after the IgScout run. The three known 15-mers belong to 
genes D7 and D14.  
Supplemental Note: Simulating CDR3 datasets 
To generate simulated immunosequencing datasets, we used the IgSimulator tool (Safonova et al., 
2015) with the set of 25 human D genes (D1-D25). For the sake of simplicity, we first assumed that all 
25 D genes participate in VDJ recombination with the same probability 0.04 (uniform distribution of 
abundances) and later analyzed a non-uniform distribution of abundances. As a variable parameter of 
the simulation, we used the maximal length of the exonuclease removal (ERmax). To simulate a 
substring of a D gene in the VDJ recombination, we randomly selected integers ERstart and ERend 
(uniformly distributed between 0 to ERmax), cropped the sequence of a D gene by ERstart nucleotides 
from the start and ERend nucleotides from the end, and added random insertions (with the length 
uniformly distributed from 0 to 10 nucleotides) on both ends. We varied ERmax from 1 to 10 (according 
to Ralph and Matsen, 2016, ERmax typically does not exceed 10 nucleotides for all D genes).  
 
IgSimulator simulates SHMs as low-frequency random mutations. Since such SHMs are unlikely to 
change the IgScout results (most mutated D segments in CDR3 will be simply excluded from analysis 
since they do not preserve k-mers), we decided not to simulate clonal lineages with abundant SHMs. 
Indeed, a new Supplemental Note “How IgScout results are affected by the number of consensus CDR3s 
and cell types?” demonstrates that IgScout shows better results on datasets with high diversity of VDJ 
recombination (datasets from PBMC / naïve / memory B cells) compared to highly mutated datasets 
with low diversity of VDJ recombination (e.g., datasets from specific plasma B cells). 
 
We simulated 10 datasets with 100,000 CDR3s each (ERmax varies from 1 to 10) for and applied 
IgScout with default parameters (k = 15, fraction = 0.001, IC = 0.5) to each of them. We assume that 
IgScout reconstructs a D gene if it reports its unique substring (i.e., a substring that does not appear in 
other D genes). Below we discuss how the length of the reconstructed D genes influences downstream 
applications of IgScout.  
 
To analyze how our ability to reconstruct low-usage D genes is affected by non-uniform distribution of 
usage of D gene, we have simulated a repertoire with a high usage of a single gene (we selected the 
longest D gene D15) and low usages of all other genes (Table A7).  
 
D gene Usage D gene Usage 
D1 0.001 D14 0.0205 
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D2 0.0025 D15 0.5620 
D3 0.0040 D16 0.0220 
D4 0.0055 D17 0.0235 
D5 0.0070 D18 0.0250 
D6 0.0085 D19 0.0265 
D7 0.0100 D20 0.0280 
D8 0.0115 D21 0.0295 
D9 0.0130 D22 0.0310 
D10 0.0145 D23 0.0325 
D11 0.0160 D24 0.0340 
D12 0.0175 D25 0.0355 
D13 0.0190 
Table A7. Simulating CDR3s with non-uniform usage of D genes. Abundance of a D gene shows the fraction 
of CDR3s in the simulated repertoire formed by this D gene. We arbitrarily assigned abundances varying from 
0.001 to 0.025 (with step 0.0015) to all genes except for D15. The sum of these abundances is 0.438 and abundance 
of D15 was set to 1 – 0.438 = 0.562.  
Supplemental Note: Benchmarking IgScout on simulated immunosequencing datasets 
We applied IgScout to simulated CDR3 datasets with uniform and non-uniform usage of D genes (see 
Supplemental Note “Simulating CDR3 datasets”).  
  
IgScout results in the case of the uniform distribution of usage of D genes. IgScout reconstructed 
24 out of 25 D genes for all values of ERmax (short 11-nucleotide long gene D25 cannot be detected 
with k = 15). On average, IgScout misses one nucleotide at the start of D gene and one nucleotide at the 
end D gene for all values of ERmax. In all simulations, IgScout returned erroneous D genes only for 
unrealistically small values ERmax = 1 and 2. Our simulation suggests that IgScout would likely 
reconstruct all D genes (except for a short D25) if their abundances were uniformly distributed.  
 
IgScout results in the case of a non-uniform distribution of usage of D genes. Figure A8 shows that 
IgScout reconstructs long D genes (> 20 nt) even if they are presented in less than 1% of CDR3s. 
IgScout missed short D genes (< 20 nt) when their abundance falls below 2.5% (D1, D4, D5, D6, D7, 
D13, D16, D18). IgScout also missed D25 because it is shorter than the default value of k=15. 
 
Figure A8. Performance of IgScout on simulated CDR3s with non-uniform usage of D genes. D genes 
reconstructed (missing) by IgScout are shown by blue (red) dots. Usages of D genes are shown in Table A7.  
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Supplemental Note: How trimmed (rather than complete) D genes affect the downstream 
analysis of immunosequencing datasets 
Two modes of IgScout applications. IgScout can be applied for:  
• inference of novel variants of known D genes (for species with known germline genes) and 
further population analysis of antibody repertoires,  
• inference of D genes (for species with unknown germline genes) and further VDJ 
classification (i.e., finding V, D, and J genes explaining the observed VDJ recombination).  
 
The first reference-based mode does not require inference of full-length D genes because they can be 
reconstructed from the trimmed D genes by aligning against the known variants of D genes (IgScout 
has a reference-based mode “--d-genes” that compares the reconstructed D genes with known ones). 
However, the negative impact of the reduced lengths of the inferred D genes on the quality of the D 
gene classification is unclear. Below we show that this impact is very small.  
 
Defining a match between a CDR3 and a D gene. Existing VDJ classification tools search for a match 
between a CDR3 and a D gene with the score exceeding a threshold L. To estimate the accuracy of the 
D gene classification, we used the datasets simulated with ERmax = 10 (that we refer to as the 
SIMULATED dataset) with uniform abundances of D genes (see Supplemental Notes “Simulating 
CDR3 datasets”).  
 
We analyzed a simple scoring based a longest match between each CDR3 from the SIMULATED 
dataset and each D gene from a database. We say that a CDR3 is generated by a specific D gene if this 
D gene results in a longest match with this CDR (over all D genes from the database). If several D genes 
provide the longest matches, we say that all of them generated a given CDR3. Since we did not simulate 
SHMs, we compute only the exact matches and thus produce more accurate results for the 
SIMULATED dataset compared to IgBlast that allows mismatches and indels. Note that an algorithm 
for D gene classification that takes into account mismatches and indels might generate less accurate 
results than an algorithm based on exact matches since it may be confused by highly similar D genes 
(e.g., it can extend an exact match by mismatches and report an incorrect D gene).  
 
False positive and false negative CDR3 classifications. Given a simulated CDR3 (referred to as 
CDR3), we refer to the D gene it originated from as D(CDR3) and to D genes with a longest match 
against this CDR3 as D*=D*(CDR3). We refer to this match as match(CDR3,D*). We further check if 
the found longest match exceeds the length threshold L and classify CDR3 as follows:  
 
1. If |match(CDR3,D*)| ³ L and match(CDR3,D*) represents a unique substring of D(CDR3), 
we classify CDR3 as a true positive (TP) and as false negative (FN) otherwise.  
2. If |match(CDR3,D*)| < L, we classify CDR3 as a true negative (TN), and a false positive (FP) 
otherwise.  
 
Using the classification of all CDRs, we compute the sensitivity as #TP / (#TP + #FN) and the specificity 
as #TN / (#TN + # FP) for values of the length threshold L varying from 5 to 15 nucleotides.  
 
We applied this procedure to the following three datasets of D genes to study the negative effects of 
trimmed D genes as compared to the full-length D genes:   
• 25 complete human D genes (referred to as the COMPLETE database)  
• 24 trimmed human D genes inferred by IgScout for the SIMULATED dataset (referred to as 
the TRIMMED database) 
• 17 highly trimmed D genes represented by the most abundant 15-mers selected by IgScout for 
inference of these D genes in the HEALTHY dataset (referred to as TRIMMED+ database) 
 
Sensitivity and specificity of the D gene classification. Figure A9 shows the sensitivity and specificity 
of the classification of an arbitrarily selected single D gene (D12) in all CDR3s generated by this D 
gene from the SIMULATED dataset. As Figure A9 illustrates, the sensitivity and specificity of the 
complete and trimmed D genes are very similar. On the other hand, the low sensitivity of the D gene 
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classification using 15-mers in the TRIMMED* dataset demonstrates that the extension of abundant 15-
mers by IgScout is an important step that significantly improves the D gene classification. 
 
 
Figure A9. Sensitivity and specificity of classifying the D12 gene in the CDR3s from the SIMULATED 
dataset. We used the COMPLETE (blue), TRIMMED (orange), and TRIMMED+ (green) datasets of D genes for 
classifying CDR3s. The length threshold L varied from 5 to 15 nucleotides. 
Figure A10 illustrates that the sensitivity/specificity of the D gene classification of complete D genes 
and trimmed D genes are nearly identical (for all values of L). Thus, trimming 1-2 nucleotides at the 
start/end of D genes hardly affects the accuracy of the D gene classification. 
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Figure A10. Sensitivity (top) and specificity (bottom) of classifying 24 inferred D genes in the SIMULATED 
dataset. Each bar represents the sensitivity (specificity) for various values of the length threshold L. Height of a 
bar shows the average value of sensitivity (specificity). Error bars shown by black lines correspond to the minimal 
and maximal values of sensitivity (specificity). 
Supplemental Note: Reconstructing variants of human D genes  
Figure A11 and Figure A12 present information about reconstructed D genes across the HEALTHY, 
ALLERGY, and HIV datasets. 
  
 
Figure A11. Human D genes that were reconstructed (green cells) and missed (white cells) by IgScout in all 
HEALTHY (top left), ALLERGY (top right), and HIV (bottom) dataset.  
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Figure A12. Information about D genes reconstructed by IgScout across all HEALTHY datasets. Position 
in a D gene is colored in dark green if it was reconstructed in at least one of the HEALTHY datasets. Positions in 
D genes that were not reconstructed in all datasets are shown in light green. Ordering of rows reflects the order in 
which IgScout discovers various D genes, e.g., D3 appears in the first row because it was reconstructed at the first 
step of IgScout in 7 out of 14 datasets, D20 appears in the second row because it was reconstructed at the first 
step of IgScout in 6 out of 14 datasets. If IgScout took n steps to analyze the i-th dataset and reconstructed a gene 
D at the j-step we assign index(D,i)=j and assign index(D,i)=n+1 if IgScout failed to reconstruct the gene D in the 
i-th dataset. All D genes are arranged from top to bottom in the increasing order of the average values of their 
indices across all fourteen datasets. Genes D1, D4, D7, D13, D18, D23, and D25 are not shown since they were 
not discovered in any of the HEALTHY datasets.  
Table A8 illustrates that IgScout finds novel variants D10+ (D15+) in 50 (46) datasets from 600 
PROJECTS10 immunosequencing datasets. It also found novel D10++ and D15++ in two datasets from 
the PRJNA308566 project and one dataset from the PRJNA308641 project, respectively (Figure A13). 
All variants of the D15 gene (D15, D15*, D15+, and D15++) differ from each other in two positions that 
can be described as 0-0, 0-1, 1-1, and 1-0 haplotypes for D15, D15*, D15+, and D15++, respectively.  
 
NCBI project Reference # datasets # datasets supporting D10+ 
# datasets 
supporting D15+ 
PRJEB18926 (21) 24 8 8 
PRJNA396773 (28) 13 13 13 
PRJNA308641 (37) 107 9 8 
PRJNA324093 (39) 95 – 3 
PRJNA248475 (40) 32 – – 
PRJNA308566 (41) 142 6 3 
PRJNA355402 (42) 93 1 1 
PRJNA393446 (43) 42 8 7 
PRJNA349143 (44) 24 – – 
PRJNA430091 (45) 28 5 3 
Table A8. Information about immunosequencing datasets in the PROJECTS10 collection supporting the 
novel D10+ and D15+ variants. The “# datasets” column shows the total number of datasets in each project.  
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Figure A13. Novel variants of D10 and D15 genes. The D10++ variant was inferred from the datasets 
SRR3099127 and SRR3099139 (project PRJNA308566) corresponding to the same individual. The D15++ variant 
was inferred from the SRR3099414 dataset (project PRJNA308641). 
Supplemental Note: Summary of IgScout results across diverse immunosequencing 
datasets  
We applied IgScout to 361 Rep-seq datasets from ten independent immunosequencing projects 
corresponding to diverse immunogenomics studies (Table A8). Figure A14 shows the sets of 
reconstructed D genes for each dataset and illustrates that 20 D genes were reconstructed across all 
datasets. In addition to 18 D genes inferred from the HEALTHY datasets, IgScout reconstructed D4 (in 
3 datasets) and D7 (in 5 datasets). Five D genes (D1, D13, D18, D23, and D25) are missing in all 
analyzed datasets. These five genes are also reported as missing in multiple studies on analyzing the 
usage of D genes: Souto-Carneiro et al., 2005, Briney et al., 2012, Elhanati et al., 2015, and Kidd et al., 
2016. For example, Briney et al., 2012 reported three D genes (D13, D18, D25) as not contributing to 
VDJ recombination in all their datasets, while Elhanati et al., 2015 reported the same three genes as 
well as six other D genes as (D4, D5, D7, D11, D22, D23) as missing in their datasets.  
 
As Figure A14 illustrates, even the most abundant D genes are missing in some datasets, e.g., D20 was 
identified in all HEALTHY datasets but was not identified in 10% of the 361 datasets. These datasets 
likely represent repertoires where a single D gene with a very high usage overpowers all others D genes 
because of a clonal selection.  
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Figure A14. Human D genes that were reconstructed (green cells) and missed (white cells) by IgScout in 
361 immunosequencing datasets from ten NCBI projects (Table A8) and the HEALTHY datasets. Datasets 
corresponding to the same NCBI project are grouped together and shown by a colored bar on the left. 14 
HEALTHY datasets are shown at the bottom of the table. The percentage of the datasets supporting inference of 
each of 25 human D genes is shown in the row “% datasets”.  
Supplemental Note: How IgScout results are affected by the number of consensus CDR3s 
and cell types?  
To evaluate how IgScout results are affected by the number of consensus CDR3s and cell types, we 
analyzed two NCBI immunosequencing projects containing 242 datasets with B cells sorted by their 
type and antigen specificity (Table A9). 
 
NCBI project # datasets description analyzed B cells analyzed tissues 
PRJNA308566 142 Hepatitis study PBMC, HBsAg+ cells, HLA-DR+ plasma cells blood 
PRJNA324093 100 Flu vaccination study (healthy donors)  
PBMC, memory, naïve, 
HA+ ASCs, HA– ASCs blood 
Table A9. Information about the PRJNA308566 and PRJNA324093 projects with 242 immunosequencing 
datasets. HBsAg+ / HLA-DR+ / HA+ refer to cells with positive response to HBsAg, HLA-DR, and 
hemagglutinin, respectively. HA– refers to cells with negative response to hemagglutinin. ASC refers to antibody 
secreting cells.  
Some of the datasets from PRJNA308566 and PRJNA308566 projects are characterized by a low 
number of consensus CDR3s (< 5000). Such low-diversity datasets likely correspond to situations when 
one clonal lineage (or a few clonal lineages) has an extremely high abundance as compared to all other 
clonal lineages. Since IgScout was not designed to analyze such datasets, it did not reconstruct any D 
genes in 75 datasets from PRJNA308566 and 49 datasets from PRJNA308566. Figure A15 presents the 
summary of IgScout results for all other datasets.   
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Figure A15. The number of inferred D genes vs the number of consensus CDR3s for datasets from the 
PRJNA308566 (left) and PRJNA324093 (right) projects. Each dataset corresponds to a single dot. Datasets 
without inferred D genes are shown as red dots. 
We also analyzed how the type of cells in a dataset affects the IgScout results. Figure A16 shows that 
IgScout results depend mainly on the number of consensus CDR3s in a dataset rather than the type of 
B cells in this dataset. As Figure A16 illustrates, IgScout reconstructed D genes even from datasets 
corresponding to highly specific B cells (e.g., HBsAg+ or ASC-HA+). However, it is important to take 
into account that the number of consensus CDR3s is correlated with the number of different VDJ 
recombinations in a dataset. Thus, a small number of VDJ recombinations, occurring in datasets with 
highly specific B cells, may lead to a small number of inferred D genes.  
 
Figure A16. IgScout results on datasets corresponding to various types of B cells in the PRJNA308566 (left) 
and PRJNA324093 (right) projects. Each bar represents datasets corresponding to the same type of B cells. The 
height of a bar shows the average number of consensus CDR3s in these datasets (in the logarithmic scale), the 
error bars show the distribution of the numbers of consensus CDR3s. Red bars correspond to datasets where 
IgScout did not infer any D genes and blue bars correspond to datasets where IgScout inferred some D genes.  
Supplemental Note: Reconstructing camel D genes 
IgScout reconstructed four D genes in the case of the Camel 1VH dataset that we refer to as D1, D2, 
D3, and D4 (Figure A17). IgScout reconstructed the same or very similar putative D genes in all camel 
datasets (Table A10) but missed D4 in datasets 2VHH, 3VH, and 3VHH (all camel D genes are shared 
between the VH and VHH datasets). Table A10 shows abundances of common 15-mers in the Camel 
1VH dataset before and after the IgScout run. 
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Figure A17. Results of the IgScout algorithm on the Camel 1VH dataset. Four inferred D genes in the Camel 
1VH dataset (top), abundances (middle) and ranks (bottom) of 15-mers from the inferred camel D genes. Details 
of this visualization are described in the legends for Figure 2 and Figure A3.   
D1 
Camel 1VH   GTACGGTGGTAGCTGGT 
Camel 1VHH  GTACGGTGGTAGCTGGT 
Camel 2VH   GTACGGTGGTAGCTGGT 
Camel 2VHH  GTACGGTGGTAGCTGGT 
Camel 3VH   GTACGGTGGTAGCTGGT 
Camel 3VHH  GTACGGTGGTAGCTGGT 
D2 
Camel 1VH      ATATTGTAGTGGTGGTTACTGCTAC 
Camel 1VHH     ATATTGTAGTGGTGGTTACTGCTAC 
Camel 2VH   CGCATACTATAGTGGTGGTTACTACTAC 
Camel 2VHH     ATATTGTAGTGGTGGTTACTGC--- 
Camel 3VH      ATATTGTAGTGGTGGTTACTGCTAC 
Camel 3VHH    CATATTGTAGTGGTGGTTACTGC--- 
D3 
Camel 1VH    TATGACTGCTATTCAGGCTCTTGGTGTTATGAC 
Camel 1VHH  GTATGACTGCTATTCAGGCTCTTGGTGTTATGAC 
Camel 2VH   GTATGACTACTGTTCAGGCTCTTGGTGTTATG-- 
Camel 2VHH  GTATGACTGCTATTCAGGCTCTTGGT-------- 
Camel 3VH    TATGACTGCTATTCAGGCTCTTGGTGTTATG-- 
Camel 3VHH   -ATGACTGCTATTCAGGCTCTTGGTG------- 
D4 
Camel 1VH   CTACTATAGCGACTATG 
Camel 1VHH  CTACTATAGCGACTATG 
Camel 2VH   CTACTATAACGAATATGAC 
Table A10. Constructing four putative camel D genes. Strings inferred for the Camel 1VH are shown in bold. 
Differences between the strings inferred for the Camel 1VH dataset and strings inferred from other datasets are 
shown in red.  
 
Figure A18. Abundances of all common 15-mers in the Camel 1VH dataset. 89 common 15-mers in the Camel 
1VH dataset have abundances varying from 48 to 474. The y–axis represents the number of common 15-mers 
with the given abundance. Red, yellow, and violet bars represent the number of common 15-mers with given 
abundance among known, mutated, and trimmed 15-mers. There exist 35 known (red bars), 14 mutated (orange 
bars), 24 trimmed (violet bars), and 16 foreign (blue bars) common 15-mers.  
Table A11 provides information about the fraction of traceable and tandem CDR3s in various camel 
datasets. Figure A19 provides information about the usage of four inferred camel D genes. Although 
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all four D genes occur in both VH and VHH antibodies, their usage varies depending on the antibody 
type. In (35), authors hypothesized that the same D and J genes are used for forming both the VH and 
VHH camel antibodies. If this hypothesis is correct, then the variations in the usage of D genes in the 
VH and VHH antibodies are most likely caused by differences between the RSSs in the V genes in the 
VH and VHH loci.  
 
dataset 
traceable CDR3s tandem CDR3s non-traceable CDR3s 
# (%) avg. length # (%) avg. length # (%) 
avg. 
length 
Camel 1VH 10,224 (22%) 55 176 (0.4%) 69 35,926 (77.6%) 54 
Camel 1VHH 8443 (21.2%) 60 222 (0.6%) 73 31,036 (78.2%) 60 
Camel 2VH 12,158 (21%) 54 183 (0.3%) 70 45,777 (78.7%) 53 
Camel 2VHH 17,356 (23.3%) 56 1292 (1.7%) 61 56,198 (76%) 54 
Camel 3VH 17,289 (21.8%) 51 1124 (1.4%) 59 60,969 (76.8%) 46 
Camel 3VHH 13546 (23%) 56 1068 (1.8%) 62 44708 (75.2%) 53 
Table A11. Classification of CDR3s across six camel immunosequencing datasets. Since only a small 
percentage of CDR3s in camel immunosequencing datasets contains 15-mers from the inferred camel D genes, 
we defined a traceable CDR3 as a CDR3 that include 15-mers with up to two mutations from 15-mers from the 
inferred camel D genes. 
 
 
Figure A19. Usage of four camel D genes across six camel datasets (left) and the similarity matrix of camel 
datasets constructed based on usages of their D genes (right). 
Figure A20 presents comparison between the four camel D genes and eight alpaca D genes listed in the 
IMGT database (camel and alpaca split ≈16 million years ago). For each camel D genes, there exists a 
similar alpaca D gene with percent identity varying from 82% to 94%.  
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Figure A20. Comparison of four camel D genes with eight alpaca D genes. (Left) Phylogenetic tree for 
combined camel (blue) and alpaca (red) D genes. (Right) Alignment of four pairs of similar camel and alpaca 
genes. Differences between camel and alpaca D genes are shown in red.  
Supplemental Note: Traceable CDR3s  
Figure A21 illustrates the usage of all human D genes across all HEALTHY datasets. Table A12 
illustrates that the percentage of traceable (tandem) CDR3s varies from 43% to 55% (0.1 – 0.2%) across 
all HEALTHY datasets. The average length of traceable, tandem, and non-traceable CDR3s is 53, 71, 
and 40 nucleotides, respectively.  
22 
 
 
 
Figure A21. Usage of human D genes across all HEALTHY datasets. (Top) Usage of human D genes in the 
Set 1 dataset (yellow bars) compared to the minimal (blue bars), average (green bars), and maximal (red bars) 
usage of D genes across all HEALTHY datasets. (Bottom) Each cell shows the percentage of CDR3s formed by 
the corresponding D gene (x-axis) in the corresponding dataset (y-axis).  
dataset traceable CDR3s tandem CDR3s non-traceable CDR3s # (%) avg. length # (%) avg. length # (%) avg. length 
Set 1 37938 (46%) 54 114 (0.1%) 72 44528 (54%) 49 
Set 2 34768 (46%) 54 161 (0.2%) 71 40470 (54%) 48 
Set 3 14492 (44%) 53 45 (0.1%) 70 18552 (56%) 48 
Set 4 47764 (50%) 53 159 (0.1%) 73 47296 (60%) 48 
Set 5 54997 (46%) 53 145 (0.1%) 68 63600 (54%) 47 
Set 6 34900 (46%) 54 122 (0.1%) 71 40886 (54%) 48 
Set 7 54180 (43%) 53 123 (0.1%) 70 70435 (56%) 47 
Set 8 31072 (46%) 53 94 (0.1%) 70 36157 (54%) 48 
Set 9 68664 (52%) 54 263 (0.2%) 72 63563 (48%) 49 
Set 10 56873 (55%) 52 127 (0.1%) 69 45700 (44%) 47 
Set 11 38381 (45%) 53 87 (0.1%) 70 45916 (54%) 48 
Set 12 54674 (48%) 51 110 (0.1%) 70 60195 (52%) 46 
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Set 13 64696 (50%) 52 109 (0.1%) 70 65721 (50%) 46 
Set 14 63610 (53%) 52 151 (0.1%) 72 55933 (47%) 47 
Table A12. Information about traceable, tandem, and non-traceable CDR3s across all HEALTHY datasets.   
Supplemental Note: D gene classification by IgScout and IgBlast 
We compared the D gene classification results generated by IgScout and IgBlast. Since IgBlast 
computes alignments for full-length immunoglobulin sequences, we analyzed raw reads for the Set1 
dataset. 1,414,503 out of 1,611,497 reads (87%) were classified as CDR3-containing reads by both 
IgBlast and DiversityAnalyzer.   
 
We classify a CDR3 as non-traceable if IgBlast reports several best D hits with the same alignment 
score. 550,514 out of 1,414,503 CDR3s (39%) are non-traceable. We also discarded 287,881 CDR3s 
(20%) because the D hits found by IgBlast are short and thus unreliable (shorter than 11 nt). For the 
remaining 576,108 CDR3s with putative D hits, we compared hits reported by IgBlast with hits reported 
by IgScout. For 504,028 out of 576,108 CDR3s (87%), IgBlast and IgScout report identical D hits. For 
4613 CDR3s, IgScout reported tandem D genes (1%). The vast majority of the remaining 12% of 
CDR3s (where IgBlast and IgScout disagreed) correspond to similar D genes (e.g., the 31-nucleotide 
long IGHD3-22 and IGHD3-9 that share a 7-mer and a 9-mer). In this case, different scoring schemes 
produce slightly different results and it is not clear how to select the best one. 
Supplemental Note: Analysis of tandem CDR3s  
IgScout identified 1900 tandem CDR3s in fourteen immunosequencing datasets corresponding to 225 
distinct pairs of D genes (D-pairs). For each D-pair, we define the D-pair abundance as the number of 
tandem CDR3s formed by D genes in the pair and classify abundant D-pairs as the D-pairs with 
abundances exceeding 1% of the number of all tandem CDR3s. 27 abundant D-pairs include 15 D genes 
and form 916 out of 1900 tandem CDR3. Figure A22 presents a graph with 16 vertices corresponding 
to D genes participating in abundant D-pairs (gene D5 corresponds to two vertices since it occurs twice 
in the IGH locus) and 27 edges (corresponding to abundant D-pairs). This graph turned out to be an 
acyclic directed graph and its topological order is the same as the order of D genes in the IGH locus. 
Thus, our analysis agrees with conclusion in (26) that the order of D genes forming tandem CDR3s 
follows their order in the IGH locus.  
 
Figure A22. Graph on 16 vertices and 27 edges corresponding to abundant D-pairs. Each abundant D-pair 
is represented by an edge from its first D gene to its second D gene.  
We compared usage of D genes in traceable CDR3s with usage of the first and second D genes in D-
pairs. Six D genes with high usage (>5%) in traceable CDR3s (D3, D10, D12, D14, D17, and D20) also 
have high usage (>5%) in tandem CDR3s (Figure A23). However, eight abundant D genes in tandem 
CDR3s (D2, D5, D6, D8, D11, D16, D19, and D24) are not abundant in traceable CDR3s.  
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Figure A23. Usage of known D genes in traceable CDR3s (green) and tandem CDR3s as the 1st (purple) 
and 2nd (orange) D gene forming a tandem CDR3. The average usage was computed across usages in all 
HEALTHY datasets.  
Table A13 presents the tandem bias and fraction of tandem CDR3s for all HEALTHY datasets. We 
classify a pair (D, D’) of D genes as direct (reverse) if all occurrences of D precede (follow) all 
occurrences of D’ in the IGH locus. A pair (D, D’) is classified as ambiguous if it is neither direct, not 
reverse. Note that only pairs including D4 or D5 gene (that have two copies in the IGH locus) can be 
classified as ambiguous. We classify a tandem CDR3 as direct/reverse/ambiguous if it is formed by 
direct/reverse/ambiguous pair of D genes. The average percentages of direct, reverse and ambiguous 
CDR3s across all HEALTHY datasets are 82%, 6%, and 12%.  
 
dataset tandem bias % of tandem CDR3s dataset tandem bias % of tandem CDR3s 
Set 1 0.10 0.20 Set 8 0.10 0.18 
Set 2 0.20 0.30 Set 9 0.04 0.25 
Set 3 0.07 0.18 Set 10 0.06 0.16 
Set 4 0.10 0.21 Set 11 0.16 0.14 
Set 5 0.05 0.16 Set 12 0.09 0.13 
Set 6 0.10 0.21 Set 13 0.06 0.11 
Set 7 0.08 0.14 Set 14 0.09 0.16 
Table A13. The tandem bias and the percentage of tandem CDR3s for all HEALTHY datasets. The column 
“% of tandem CDR3” shows the percentage of tandem CDR3 among all traceable CDR3s for each 
immunosequencing dataset.  
Figure A24 demonstrates that the percentage and length of tandem CDR3s in the ALLERGY BM 
datasets is higher than in the ALLERGY PBMC and HIV PBMC datasets.  
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Figure A24. The percentages (left) and lengths (right) of tandem CDR3s in ALLERGY (bone marrow), 
ALLERGY (PBMC), and HIV (PBMC) datasets.   
Figure A25 shows the tandem matrix constructed based on pairs of D genes forming tandem CDR3s in 
15 datasets corresponding to the hepatitis patient 1776 analyzed in (37). The large number of entries in 
the D20 row in the lower part of this matrix suggests that the D20 gene is duplicated in this patient.  
 
Figure A25. The tandem matrix for D genes forming tandem CDR3s in the datasets corresponding to the 
hepatitis patient 1776 (37). 
Supplemental Note: Ultra-long tandem CDR3s  
We analyzed inter-D insertions in all 1900 tandem CDR3s across all HEALTHY datasets. These tandem 
CDR3s contain 1081 distinct inter-D insertions, varying in length from 0 to 153 nucleotides (Figure 
A26). 384 of them have length at least 10 nucleotides. Since most of them do not share significant 
similarities, they likely correspond to randomly generated sequences.  
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Figure A26. Distribution of lengths of inter-D insertions in tandem CDR3s across all HEALTHY datasets. 
Two ultra-long inter-D insertions (of length 153 nucleotides) are not shown.  
Two longest inter-D insertions (denoted I1 and I2) appear in the Set 1 and have length 153 nucleotides. 
They are formed by genes D9 and D10, differ by a single nucleotide, and appear in CDR3s differing by 
six nucleotides (Figure A27, top). The inter-D insertion I2 starts with the right RSS of D9 and ends with 
the left RSS of D10 (Figure A27, bottom).  
 
 
Figure A27. Ultra-long tandem CDR3s. (Top) Alignment of tandem CDR3s formed by genes D9 (yellow) and 
D10 (green) and containing ultra-long inter-D insertions I1 (blue) and I2 (red). (Bottom) Fragment of the IGH 
locus starting with the left RSS sequence of the D9 gene and ending with the right RSS sequence of the D10 gene. 
Left RSS sequences are shown as concatenates of a nonamer (shown in blue), a 12-nucleotide long spacer (shown 
in italic), and a heptamer (shown in blue). Right RSS sequences are shown as concatenates of a heptamer (shown 
in blue), a 12-nucleotide long spacer (shown in italic), and a nanomer (shown in blue). 
Supplemental Note: De novo reconstruction of human J genes  
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All human J genes are located in a 2 kb long region in the human IGH locus (Table A14). Table A15 
and Figure A28 show allelic variants of human J genes listed in the IMGT database.  
 
Name IMGT name Position (bp) Length (nt) 
J1 IGHJ1 1,178,312 52 
J2 IGHJ2 1,178,520 53 
J3 IGHJ3 1,179,132 50 
J4 IGHJ4 1,179,504 48 
J5 IGHJ5 1,179,905 51 
J6 IGHJ6 1,180,521 63 
Table A14. Positions and lengths of J genes on the 14th chromosome in the human genome. Since the IGH 
locus starts at the end of the 14th chromosome, positions are given with respect to its reverse complementary 
sequence.  
J gene IMGT allele ID 
J1 IGHJ1*01 J1 
J2 IGHJ2*01 J2 
J3 IGHJ3*01 J3* IGHJ3*02 J3 
J4 
IGHJ4*01 J4* 
IGHJ4*02 J4 
IGHJ4*03 J4** 
J5 IGHJ5*01 J5 IGHJ5*02 J5* 
J6 
IGHJ6*01 J6* 
IGHJ6*02 J6 
IGHJ6*03 J6** 
IGHJ6*04 J6*** 
Table A15. Information about variants of J genes and their correspondence with alleles listed in the IMGT 
database.  
 
Figure A28. Allelic variants of human J genes. Differences between various variants are highlighted in red. 
De novo reconstruction of J genes requires immunosequencing reads that cover the entire J genes.  This 
is not the case for many immunosequencing datasets, including all HEALTHY datasets. We 
benchmarked how IgScout reconstructs human J genes using the ALLERGY (rather than HEALTHY) 
datasets since reads in these datasets cover the entire J segment.  
 
We combined four datasets corresponding to the first allergic donor and identified 5,940,059 fragments 
of J genes in reads from this dataset using IgReC, resulting in the set of strings Jtrimmed. Afterwards, we 
applied IgScout to infer J genes from these strings. Since J genes are longer than D genes, we increased 
the parameter k-mer size from 15 to 40 (all 40-mers in J genes are unique, i.e., they appear in a single J 
gene). The human J genes (from J1 to J6) contain 83 40-mers (192 40-mers including their alleles listed 
in the IMGT database). The Jtrimmed dataset contains all 40-mers appearing in six human J genes.  
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We classify a k-mer as known if it occurs in a human J gene (from J1 to J6), mutated if it differs from a 
known k-mer by a single nucleotide, and trimmed if it contains a known (k-2)-mer. All other k-mers are 
classified as foreign. 41% of strings in the Jtrimmed dataset contain a known 40-mer. 43% strings in the 
Jtrimmed dataset contain either a known, or a mutated, or a trimmed 40-mer.  
 
Since the number of J genes is smaller than the number of D genes (6 vs 25), we increased the fraction 
parameter to 0.02 for the case of the J gene finding, i.e., a k-mer is classified as common if its abundance 
exceeds 2% of the number of sequences in the Jtrimmed set. Figure A29 presents distribution of 
abundances of all 47 common 40-mers in the Jtrimmed set. Figure A30 shows that the usages of human J 
genes are similar for various ALLERGY datasets.  
 
Figure A29. Abundances of all 47 common 40-mers in the Jtrimmed set. 47 common 40-mers in the Jtrimmed set 
have abundances varying from 119,082 to 1,079,233. The y–axis represents the number of common 40-mers with 
given abundance. All 47 common 40-mers are known (shown as red bars). Each bar represents the number of 
common 40-mers with given abundance. The histogram represents 29 bins of width 10,000 each. 
 
Figure A30. Usage of human J genes in the ALLERGY datasets. We merged four datasets corresponding to 
each of six ALLERGY donors and computed the J gene usage for each donor.  
We applied IgScout to the Jtrimmed dataset with k = 40. Ranks and abundances of known 40-mers are 
shown in Figure A31. IgScout reconstructed four strings representing the complete sequences of the J3, 
J4, J5, and J6 genes (Figure A32). The J1 and J2 genes were not reconstructed by IgScout since their 
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most abundant 40-mers do not pass the fraction threshold (the most abundant 40-mer from the J1 and 
J2 genes are supported by 30,000 and 99,000 CDR3s, respectively.  
 
 
 
Figure A31. Ranks (top) and abundances (bottom) of 40-mers from human J genes (Jtrimmed set). Details of 
this visualization are described in the legend for Figure A3. Abundances exceeding 100,000 are shown in red.  
 
Figure A32. Results of the IgScout algorithm on the Jtrimmed dataset. Details of this visualization are described 
in the legend for Figure 2. 
Since IgDiscover (18) is limited to de novo reconstruction of V genes, IMPre (19) is the only available 
tool for de novo reconstruction of J genes. Since IMpre demonstrates the best results on sequences 
trimmed by the ends of J genes, we trimmed suffixes of reads corresponding to constant regions. We 
applied IgScout and IMPre to 6 donors from the ALLERGY dataset and compared the J genes inferred 
by IgScout and IMPre (Figure A33).  
 
We classify an inferred segment as erroneous if it was formed by an addition of incorrect nucleotides 
to the start of a J gene. IgScout reconstructed four out of six human J genes over their entire lengths 
(including the known variant J6**) and made no errors. IMPre reconstructed all six J genes (including 
the known variants J3* and J6**) but made seven errors. While IgScout reconstructs complete D genes, 
IMPre misses 2.3 nucleotides on average at the start of the reconstructed J genes.  
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Both IgScout and IMPre reported 3 novel variants of J genes each. However, since all these six variants 
are different, they are likely caused by frequent SHMs in J genes and thus require additional tuning of 
both tools for de novo reconstruction of J genes.  
 
  
 
 
Figure A33. De novo reconstructions of J genes for six ALLERGY patients using using IgScout (top) and 
IMPre (bottom). Details of this visualization are described in the legends for Figure 3 and Figure A3. Some 
reported sequences represent inaccurately reconstructed J genes (e.g., a J gene with several added nucleotides at 
the start) that we represented using red circles.  
Supplemental Note: List of tandem CDR3s 
Figure A34 lists all 114 tandem CDR3s in the Set 1 dataset. 
 
Figure A34. List of 114 tandem CDR3s in the Set 1 dataset. All 114 tandem CDR3s can be found at 
https://drive.google.com/open?id=141FtIZBH3RMNyVBmNbfJIucn4lYBeHgB.  
